Compare WOOF & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WOOF | ANL |
|---|---|---|
| Founded | 1965 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 762.1M | 611.1M |
| IPO Year | 2020 | 2022 |
| Metric | WOOF | ANL |
|---|---|---|
| Price | $2.70 | $13.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | $4.06 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 1.4M | 148.1K |
| Earning Date | 06-04-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,961,467,000.00 | N/A |
| Revenue This Year | $2.64 | $36.02 |
| Revenue Next Year | $1.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.24 | $0.88 |
| 52 Week High | $3.96 | $17.25 |
| Indicator | WOOF | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 48.73 | 55.96 |
| Support Level | $2.70 | $12.45 |
| Resistance Level | $2.80 | $15.32 |
| Average True Range (ATR) | 0.11 | 0.94 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 28.72 | 56.99 |
Petco Health and Wellness Co Inc is a pet specialty retailer focused on improving the lives of pets, pet parents, and its own partners with pet care centers in approximately 50 states, the District of Columbia and Puerto Rico. The Company also offers an expanded range of consumables, supplies, and services through its website and mobile app.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.